期刊
DIABETES CARE
卷 36, 期 8, 页码 2154-2161出版社
AMER DIABETES ASSOC
DOI: 10.2337/dc12-2391
关键词
-
资金
- Janssen Research & Development, LLC
- Janssen Global Services, LLC
- National Institutes of Health
- National Institute of Diabetes and Digestive and Kidney Diseases
- DVA
- Amylin Pharmaceuticals, Inc.
- AstraZeneca Pharmaceuticals LP
- Bristol-Myers Squibb Company
- Johnson Johnson
- Lilly Pharmaceuticals
- Novartis Pharmaceuticals Corporation
- Sanofi
- Daiichi-Sankyo, Inc.
- Novo Nordisk Pharmaceuticals, Inc.
OBJECTIVECanagliflozin, a sodium glucose cotransporter (SGLT) 2 inhibitor, is also a low-potency SGLT1 inhibitor. This study tested the hypothesis that intestinal canagliflozin levels postdose are sufficiently high to transiently inhibit intestinal SGLT1, thereby delaying intestinal glucose absorption.RESEARCH DESIGN AND METHODSThis two-period, crossover study evaluated effects of canagliflozin on intestinal glucose absorption in 20 healthy subjects using a dual-tracer method. Placebo or canagliflozin 300 mg was given 20 min before a 600-kcal mixed-meal tolerance test. Plasma glucose, H-3-glucose, C-14-glucose, and insulin were measured frequently for 6 h to calculate rates of appearance of oral glucose (RaO) in plasma, endogenous glucose production, and glucose disposal.RESULTSCompared with placebo, canagliflozin treatment reduced postprandial plasma glucose and insulin excursions (incremental 0- to 2-h area under the curve [AUC(0-2h)] reductions of 35% and 43%, respectively; P < 0.001 for both), increased 0- to 6-h urinary glucose excretion (UGE(0-6h), 18.2 5.6 vs. <0.2 g; P < 0.001), and delayed RaO. Canagliflozin reduced AUC RaO by 31% over 0 to 1 h (geometric means, 264 vs. 381 mg/kg; P < 0.001) and by 20% over 0 to 2 h (576 vs. 723 mg/kg; P = 0.002). Over 2 to 6 h, canagliflozin increased RaO such that total AUC RaO over 0 to 6 h was <6% lower versus placebo (960 vs. 1,018 mg/kg; P = 0.003). A modest (approximate to 10%) reduction in acetaminophen absorption was observed over the first 2 h, but this difference was not sufficient to explain the reduction in RaO. Total glucose disposal over 0 to 6 h was similar across groups.CONCLUSIONSCanagliflozin reduces postprandial plasma glucose and insulin by increasing UGE (via renal SGLT2 inhibition) and delaying RaO, likely due to intestinal SGLT1 inhibition.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据